192 related articles for article (PubMed ID: 35026193)
1. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.
Abdollahi E; Keyhanfar F; Delbandi AA; Falak R; Hajimiresmaiel SJ; Shafiei M
Eur J Pharmacol; 2022 Mar; 918():174715. PubMed ID: 35026193
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-
Lee N; Heo YJ; Choi SE; Jeon JY; Han SJ; Kim DJ; Kang Y; Lee KW; Kim HJ
J Immunol Res; 2021; 2021():9944880. PubMed ID: 34124273
[TBL] [Abstract][Full Text] [Related]
3. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
6. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation.
Faridvand Y; Kazemzadeh H; Vahedian V; Mirzajanzadeh P; Nejabati HR; Safaie N; Maroufi NF; Pezeshkian M; Nouri M; Jodati A
Clin Exp Pharmacol Physiol; 2022 Jun; 49(6):643-651. PubMed ID: 35274762
[TBL] [Abstract][Full Text] [Related]
10. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-
Liu L; Luo H; Liang Y; Tang J; Shu Y
Comput Math Methods Med; 2022; 2022():3293054. PubMed ID: 35096128
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
[TBL] [Abstract][Full Text] [Related]
13. Anti-Inflammatory Activity of Adenosine 5'-Trisphosphate in Lipopolysaccharide-Stimulated Human Umbilical Vein Endothelial Cells Through Negative Regulation of Toll-Like Receptor MyD88 Signaling.
Luo X; Xiao B; Xiao Z
DNA Cell Biol; 2019 Dec; 38(12):1557-1563. PubMed ID: 31580158
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin Attenuates Na
Ye Y; Jia X; Bajaj M; Birnbaum Y
Cardiovasc Drugs Ther; 2018 Dec; 32(6):553-558. PubMed ID: 30367338
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
[TBL] [Abstract][Full Text] [Related]
16. Geraniin Inhibits LPS-Induced THP-1 Macrophages Switching to M1 Phenotype via SOCS1/NF-κB Pathway.
Liu X; Li J; Peng X; Lv B; Wang P; Zhao X; Yu B
Inflammation; 2016 Aug; 39(4):1421-33. PubMed ID: 27290719
[TBL] [Abstract][Full Text] [Related]
17. Isotrifoliol inhibits pro-inflammatory mediators by suppression of TLR/NF-κB and TLR/MAPK signaling in LPS-induced RAW264.7 cells.
Li H; Yoon JH; Won HJ; Ji HS; Yuk HJ; Park KH; Park HY; Jeong TS
Int Immunopharmacol; 2017 Apr; 45():110-119. PubMed ID: 28192731
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
[TBL] [Abstract][Full Text] [Related]
19. Anti-Inflammatory Activity of Tanshinone IIA in LPS-Stimulated RAW264.7 Macrophages via miRNAs and TLR4-NF-κB Pathway.
Fan G; Jiang X; Wu X; Fordjour PA; Miao L; Zhang H; Zhu Y; Gao X
Inflammation; 2016 Feb; 39(1):375-384. PubMed ID: 26639663
[TBL] [Abstract][Full Text] [Related]
20. Quercetin attenuates atherosclerotic inflammation and adhesion molecule expression by modulating TLR-NF-κB signaling pathway.
Bhaskar S; Sudhakaran PR; Helen A
Cell Immunol; 2016 Dec; 310():131-140. PubMed ID: 27585526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
